What is Gravity Diagnostics?
Gravity Diagnostics operates as a high-complexity, CAP-accredited, and CLIA-certified laboratory, providing a comprehensive suite of diagnostic services. Its portfolio spans critical health sectors, including toxicology, pharmacogenetics, respiratory diagnostics, and blood hematology. By maintaining licensure across all 50 states, the company serves as a vital partner for physicians and healthcare systems, emphasizing regulatory compliance and clinical precision. The firm's business model is built upon the intersection of high-throughput testing capabilities and a commitment to patient-centric outcomes, positioning it as a key player in the evolving landscape of diagnostic medicine.
How much funding has Gravity Diagnostics raised?
Gravity Diagnostics has raised a total of $5.3M across 2 funding rounds:
Debt
$350K
Other Financing Round
$5M
Debt (2020): $350K with participation from PPP
Other Financing Round (2025): $5M led by The Community Development Venture Capital Alliance and Advantage Capital
Key Investors in Gravity Diagnostics
The Community Development Venture Capital Alliance
The Community Development Venture Capital Alliance (CDVCA) is a network dedicated to the community development venture capital industry, providing flexible equity risk capital to businesses in low-income communities to foster economic growth.
Advantage Capital
Advantage Capital Partners is a venture capital firm that invests in diverse sectors including cleantech, communication, energy, information technology, and life sciences.
PPP
Public-Private Partnership
What's next for Gravity Diagnostics?
With the recent influx of capital, Gravity Diagnostics is well-positioned to accelerate its strategic growth initiatives. The company is expected to leverage this financing to enhance its laboratory automation, expand its diagnostic test menu, and potentially increase its footprint in underserved markets. As the healthcare industry shifts toward more personalized and rapid diagnostic solutions, Gravity Diagnostics' focus on pharmacogenetics and specialized testing will likely serve as a primary driver for long-term value creation. The firm's ability to maintain rigorous quality standards while scaling operations will be the defining factor in its continued market leadership.
See full Gravity Diagnostics company page
